This preview shows page 1. Sign up to view the full content.
Unformatted text preview: assumed that the appropriate representation of dose level has been de- termined prior to specification of the dose-toxicity model. 1.3. Choice of Starting Dose In cancer therapy, the phase I trial often represents the first time a particular treatment regimen is being administered to humans. Due to consequent safety considerations, the starting dose in a cancer phase I trial is traditionally a low dose at which no significant toxicity is anticipated. For example, the initial dose is frequently selected on the basis of preclinical investigation to be one-tenth of the murine equivalent LD 10 (the dose that produces 10% mortality in mice) or one-third the toxic dose low (first toxic dose) in dogs (Geller, 1984; Penta et al., 1992). Conversely, several authors (e.g., OQuigley et al., 1990) suggest that the starting dose should correspond to the experimenters best prior estimate of the MTD, which may not be a conservative initial level. This may be appropriate since starting the trial at a dose level significantly below the...
View Full Document
This note was uploaded on 06/13/2011 for the course PHYSICS 101 taught by Professor Shu during the Spring '11 term at FIU.
- Spring '11